Résumé
Resumen La obesidad es una enfermedad crónica, con afección sistémica y de carácter multifactorial que constituye un grave problema de salud pública, considerada por la Organización Mundial de la Salud una epidemia global. La obesidad es resultado del equilibrio energético positivo por tiempo prolongado, donde la energía derivada de los alimentos excede la energía gastada en la vida cotidiana. En vía de poner fin a este problema de salud pública se han buscado opciones de tratamiento, si bien las modificaciones al estilo de vida, incluida la dieta y el ejercicio, siguen siendo la piedra angular del tratamiento de la obesidad, estas modificaciones no han permitido mantener resultados a largo plazo, por esta razón los medicamentos contra la obesidad se vuelven una opción viable. Son cinco los medicamentos aprobados por la Dirección de Alimentos y Fármacos de Estados Unidos para el tratamiento a largo plazo de la obesidad: orlistat, fentarmina/topiramato de liberación prolongada, lorcarserina, naltrexona/bupropión de liberación prolongada y liraglutida, mismos que han demostrado eficacia y seguridad necesaria para tomarse en cuenta como una opción terapéutica. En este artículo revisaremos la eficacia y seguridad de cada uno los medicamentos aprobados contra la obesidad que se encuentran disponibles.
Abstract Obesity is a chronic disease, with systemic affection and of multifactorial character that constitutes a serious problem of public health, being considered by the World Health Organization a global epidemic. Obesity is the result of a positive energy balance by a long time, where the energy derived from food exceeds the energy expended in everyday life. In order to put an end to this public health problem, treatment options have been sought, although the modifications to the lifestyle included diet and exercise are still the cornerstone of the treatment for obesity, these modifications have not allowed to maintain long-term results; for this reason anti-obesity drugs become a viable option. There are five drugs approved by the FDA nowadays for the long-term treatment of obesity: orlistat, phentermine/topiramate prolonged release, lorcarserin, naltrexone/bupropion prolonged release, and liraglutide, which have shown efficacy and the necessary safety to be taken into account as a therapeutic option. In this article we will review the effectiveness and safety of each of the approved anti-obesity drugs that are available.
Résumé
Antecedentes. Las tendencias de obesidad y sobrepeso en México muestran un significativo incremento en las últimas encuestas nacionales. Esto se ve reflejado en el incremento de las enfermedades crónicas no transmisibles, además de un mayor consumo de agentes para pérdida de peso. Objetivo. Encontrar la relación entre el consumo de productos adelgazantes, el sobrepeso y la obesidad en profesores de una universidad privada de Puebla, México. Materiales y métodos. Se realizó un diseño no experimental, transversal descriptivo, utilizando un muestreo probabilístico aleatorio simple, en el que participaron 100 profesionistas; 27 hombres y 73 mujeres. Se aplicó un cuestionario para conocer los hábitos, el consumo de agentes para pérdida de peso, además de mostrárseles modelos anatómicos que determinaron la percepción de la persona con su cuerpo. Finalmente se realizó la medición antropométrica y se obtuvo el cálculo de su índice de masa corporal (IMC). Resultados. El 45% de las personas involucradas presentan sobrepeso y obesidad.38% consumen productos para bajar de peso; de estos, 84,2% eran mujeres. Entre mayor índice de masa corporal (IMC) mayor consumo de productos para bajar de peso (p<0.05). Se observa una relación inversa entre mayor obesidad y menor número de comidas al día, a la par con un menor número de horas de ejercicio. Finalmente, la mayoría de las personas con sobrepeso se perciben con un IMC mayor. Conclusión. El consumo de agentes para pérdida de peso se relaciona con el incremento del sobrepeso y la obesidad en los profesionistas.
Background. Current tendencies in obesity and overweight in México shows a significant increase in the last National Nutrition and Health Surveys, which is reflected in the rise of chronic non-transmissible diseases and an increase of anti-obesity drugs. Objective. Find the relationship between the consumption of anti-obesity drugs, overweight and obesity in teachers at a private university of Puebla city, in Mexico. Materials and methods. This is a non-experimental, cross-sectional descriptive design, where a simple random probability sampling was used. 100 professional workers at a private university of Puebla city participated, 27 men and 73 women. It was applied a test to each one of them, in order to identify their habits and consume of anti-obesity drugs. Anatomical models were presented to the participants to determinate their self-perception of body image. Finally anthropometric measures were done and body mass index was calculated. Results. 45% of participants presented overweight and obesity; 38% consume anti-obesity drugs, of these, 84.2% are women. It was observed that higher body mass index (BMI) gives a higher consume of anti-obesity drugs (p<0.05). It was determined an inversed relationship between a higher obesity degree and a lower number of meals a day, correlated also with a lower number of exercise hours. Finally people with a healthy BMI, have adequate self-perception of body image and the majority of people with overweight, perceived themselves with a higher BMI. Conclusions. The consumption of anti-obesity drugs is related to the increase of overweight and obesity in professional workers.
Résumé
Central obesity have an important impact on the development of risk factors for coronary heart disease, including dislipidemia, glucose intolerance, insulin resistance and hypertension. These factors contribute to building cardiovascular (CV) disease as a major cause of death. The approach to obesity therapy should be designed to reduce CV risk and mortality. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but the resultant weight loss is often small and long-term success is uncommon and disappointing. Drug therapy is considered for individuals with a body mass index greater than 30 kg/m² or ranging from 25 to 30 kg/m² if they have comorbid conditions. Antiobesity agents can be helpful to some patients in achieving and maintaining meaningful weight loss, but yet our pharmaceutical tools are of limited effectiveness considering the magnitude of the problem. At the present, only two drugs, orlistat and sibutramine, are approved for long-term treatment of obesity and promote no more than 5 to 10 percent of weight loss. Rimonabant, a cannabinoid-1 receptor antagonist, was withdrawn from the market because of concerns about its safety, including risk of suicidal and seizures, although very effective in promoting clinically meaningful weight loss, reduction in waist circumference, and improvements in several metabolic risk factors, rimonabant, a cannabinoid-1 receptor antagonist was withdrawn from the market because it concerns about its safety, including risk of suicidal and seizures. Fortunately, recent fundamental insights into the neuroendocrine mechanisms regulating body weight provide an expanding list of molecular targets for novel, rationally designed antiobesity drugs. In this review, the therapeutic potential of some antiobesity molecules in the development will be analyzed based on an understanding of energy homeostasis.
Obesidade e, particularmente, a obesidade central têm influência importante na predisposição a fatores de risco para doença coronariana, incluindo dislipidemia, intolerância à glicose, resistência à insulina e hipertensão. Tais fatores contribuem para tornar as doenças cardiovasculares (DC) causas frequentes de morte. Os métodos de tratamento da obesidade deveriam ser voltados à redução do risco e da mortalidade devido às doenças cardiovasculares. Dietas e mudanças no estilo de vida continuam sendo fatores-chave no tratamento à obesidade, mas a perda de peso resultante é geralmente pequena e o sucesso em longo prazo costuma ser incomum e frustrante. O tratamento com medicamentos é indicado para indivíduos com índice de massa corpórea superior a 30 kg/m² ou entre 25 e 30 kg/m², se apresentarem comorbidades. Agentes antiobesidade podem ajudar alguns pacientes a alcançar e manter uma perda de peso significativa, mas, ainda assim, os agentes farmacológicos são pouco efetivos considerando-se a magnitude do problema. Atualmente, apenas duas drogas, orlistat e sibutramina, são consideradas efetivas para tratamentos em longo prazo, promovendo não mais do que 5 por cento a 10 por cento de perda de peso. Embora seja muito eficaz ao promover perda de peso significativa do ponto de vista clínico, redução da circunferência da cintura e melhora no perfil metabólico, o rimonabanto, um antagonista do receptor canabinoide 1, foi retirado do mercado por fatores relacionados à segurança, incluindo a ocorrência de suicídios e convulsões. Felizmente, conhecimentos fundamentais recentes sobre mecanismos neuroendócrinos que regulam o peso corporal forneceram uma lista considerável de alvos moleculares para novas drogas antiobesidade produzidas racionalmente. Nesta revisão de literatura, a eficácia terapêutica de algumas moléculas antiobesidade será analisada com base no entendimento da homeostase energética.